Neglected Tropical Disease Treatments global market is likely to reach $2.6 billion by 2021Highlights

News provided by

Jun 19, 2017, 15:28 ET

NEW YORK, June 19, 2017 /PRNewswire/ -- The global market for neglected tropical diseases should reach $2.6 billion by 2021 from $1.4 billion in 2016 at a compound annual growth rate (CAGR) of 14.1%, from 2016 to 2021.

• The market for malaria treatments is expected to grow from $513.5 million in 2016 to $757.9 million in 2021 at a CAGR of 8.1% for the period 2016-2021.

• The dengue (vaccine) segment of the neglected tropical diseases market is expected to grow from $299.4 million in 2016 to $1.3 billion in 2021 at a CAGR of 34.8% for the period 2016-2021.

• Tropical diseases such as malaria, leishmaniasis, schistosomiasis, lymphatic filariasis, Chagas disease, African trypanosomiasis, dengue — and now Ebola and Zika — are common in the tropical and subtropical regions of the world.

• These conditions, often collectively referred to as "Neglected Tropical Diseases," have attracted limited interest from the industry due to their impact being primarily confined to marginalized communities.

• The disease burden, however, is not restricted to these areas since vectors and parasites can often spread to other regions via travelers or cargo.

• The report provides an overview of neglected tropical diseases and explores evolving treatment options and market opportunities.

• The global market for neglected tropical diseases should reach $2.6 billion by 2021 from $1.4 billion in 2016 at a compound annual growth rate (CAGR) of 14.1%, from 2016 to 2021.• The market for malaria treatments is expected to grow from $513.5 million in 2016 to $757.9 million in 2021 at a CAGR of 8.1% for the period 2016-2021.• The dengue (vaccine) segment of the neglected tropical diseases market is expected to grow from $299.4 million in 2016 to $1.3 billion in 2021 at a CAGR of 34.8% for the period 2016-2021.Chapter 1: IntroductionTropical diseases such as malaria, leishmaniasis, schistosomiasis, lymphatic filariasis, Chagas disease, African trypanosomiasis, dengue — and now Ebola and Zika — are common in the tropical and subtropical regions of the world. These conditions, often collectively referred to as "Neglected Tropical Diseases," have attracted limited interest from the industry due to their impact being primarily confined to marginalized communities. The disease burden, however, is not restricted to these areas since vectors and parasites can often spread to other regions via travelers or cargo. Every year, malaria alone results in one to three million deaths out of approximately half a billion cases, while many more go undetected or undiagnosed. More than a billion people are affected by denguewhich is endemic in over 100 countries and indications now prevail in tropical and subtropical conditions in about 150 countries.Of the 850 therapeutic products approved between 2000 and 2011, only 4% (and only 1% of all approved new chemical entities or NCEs) were indicated for neglected tropical diseases even though these conditions account for 11% of the global disease burden. Although Ebola and Zika are now on the world radar and efforts are underway to discover vaccines, others such as Chagas disease have marketed therapies that only manage symptoms.Study Goals and ObjectivesThe report provides an overview of neglected tropical diseases and explores evolving treatment options and market opportunities. Market deterrents, unmet needs and other factors that drive research are also discussed, while patents that highlight research priorities and predict future trends are analyzed.The report examines regions as defined by the World Health Organization (WHO) and details estimated market size as well as forecasts through 2021 by region and disease. It also describes the contributions, investments and portfolios of some of the key players in this domain.Reasons for Doing This StudyPharmaceutical companies and research institutions prioritize research based on the needs of the market. Research and development is based on the return on investment dictated by market demand and consumer purchasing power. While the burden of tropical diseases and their unmet needs are huge,investment has been limited because the conditions affect communities that cannot afford exorbitant healthcare expenses. However, with initiatives from organizations like the WHO, the Gates Foundation and collaborative research platforms like the Drugs for Neglected Diseases Initiative (DNDi), pharmaceutical and biotechnology players are now working together to support drug discovery and development. Due to the increased mobility of travelers and cargo, tropical diseases are no longer restricted to endemic regions and have now emerged in new areas, further highlighting the need for companies to focus theirefforts on these debilitating and often deadly conditions.The morbidity associated with recent outbreaks of Ebola and Zika have highlighted the unpreparedness of both the industry and government in dealing with viruses that were once endemic to regions such as Africa. The need for drug development for these indications is greater than ever and this study providesan overview of the collaborations, upcoming product launches and other factors driving the market. Some of the currently marketed "Gold standard treatments" have started to prove ineffective due to the emergence of parasite resistance, necessitating the need for the discovery of drugs with differentmechanisms of action. This report includes market intelligence on some of the newer candidates in the drug development pipeline, listed by disease, as well as patents being filed.Scope of ReportThe report focuses on newer drugs and innovations in chemical compounds, vaccines and biologicals recently launched or in development. Specifically excluded from the scope of research are vector or mosquito control approaches, strategies and products; drugs used for symptomatic treatment and notfor the elimination of the virus from the host; and details on manufacturers and suppliers of nonbranded generics. Products used for diagnosis as well as PCR techniques, kits and testing facilities are also excluded from the report. BCC Research has categorized the markets based on regions defined by the WHO since it is the primary organization mapping disease prevalence, assisting with access to medicine and enabling partnerships. Regions include Africa, Americas, South-East Asia, Europe, Eastern Mediterranean and Western Pacific. These cover all the WHO participating countries which are described in detail in the subsequent section.Information SourcesBCC Research conducted a comprehensive literature search that included technical newsletters, published patent applications, company public releases, whitepapers and journals, and several other sources. Data were collected through interviews and correspondence with key opinion leaders in the industry.MethodologyBoth primary and secondary research methodologies were used in preparing this study. Projections were based on estimates such as disease incidence, coverage of vaccine programs and the WHO's access to medicine programs.Geographic BreakdownIn this report, areas considered for market analysis include the six regions defined by the WHO:Africa• Algeria• Angola• Benin• Botswana• Burkina Faso• Burundi• Cameroon• Cabo Verde• Central African Republic• Chad• Comoros• Congo• Côte d'Ivoire• Democratic Republic of the Congo• Equatorial Guinea• Eritrea• Ethiopia• Gabon• Gambia• Ghana• Guinea• Guinea-Bissau• Kenya• Lesotho• Liberia• Madagascar• Malawi• Mali• Mauritania• Mauritius• Mozambique• Namibia• Niger• Nigeria• Rwanda• Sao Tome and Principe• Senegal• Seychelles• Sierra Leone• South Africa• South Sudan• Swaziland• Togo• Uganda• United Republic of Tanzania• Zambia• ZimbabweAmericas• Antigua and Barbuda• Argentina• Bahamas• Barbados• Belize• Bolivia• Brazil• Canada• Chile• Colombia• Costa Rica• Cuba• Dominica• Dominican Republic• Ecuador• El Salvador• Grenada• Guatemala• Guyana• Haiti• Honduras• Jamaica• Mexico• Nicaragua• Panama• Paraguay• Peru• Saint Kitts and Nevis• Saint Lucia• Saint Vincent and the Grenadines• Suriname• Trinidad and Tobago• The U.S.• Uruguay• VenezuelaSouth-East Asia• Bangladesh• Bhutan• Democratic People's Republic of Korea• India• Indonesia• Maldives• Myanmar• Nepal• Sri Lanka• Thailand• Timor-LesteEurope• Albania• Andorra• Armenia• Austria• Azerbaijan• Belarus• Belgium• Bosnia and Herzegovina• Bulgaria• Croatia• Cyprus• Czech Republic• Denmark• Estonia• Finland• France• Georgia• Germany• Greece• Hungary• Iceland• Ireland• Israel• Italy• Kazakhstan• Kyrgyzstan• Latvia• Lithuania• Luxembourg• Malta• Monaco• Montenegro• Netherlands• Norway• Poland• Portugal• Republic of Moldova• Romania• The Russian Federation• San Marino• Serbia• Slovakia• Slovenia• Spain• Sweden• Switzerland• Tajikistan• Republic of Macedonia• Turkey• Turkmenistan• Ukraine• The U.K.• UzbekistanEastern Mediterranean• Afghanistan• Bahrain• Djibouti• Egypt• Islamic Republic of Iran• Iraq• Jordan• Kuwait• Lebanon• Libya• Morocco• Oman• Pakistan• Qatar• Saudi Arabia• Somalia• Sudan• Syrian Arab Republic• Tunisia• United Arab Emirates• YemenWestern Pacific• Australia• Brunei Darussalam• Cambodia• China• Cook Islands• Fiji• Japan• Kiribati• Lao People's Democratic Republic• Malaysia• Marshall Islands• Federated States of Micronesia• Mongolia• Nauru• New Zealand• Niue• Palau• Papua New Guinea• Philippines• Republic of Korea• Samoa• Singapore• Solomon Islands• Tonga• Tuvalu• Vanuatu• VietnamRead the full report: http://www.reportlinker.com/p04948622/Global-Markets-for-Neglected-Tropical-Disease-Treatments.htmlAbout Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.http://www.reportlinker.com__________________________Contact Clare: [email protected]: (339)-368-6001Intl: +1 339-368-6001